Back HIV/AIDS HIV/AIDS Topics HIV Treatment

AIDS 2016: Seeking a Cure, Doctors Document Bone Marrow Transplant Recipients with HIV

The "Berlin patient," Timothy Ray Brown, has now survived 7 years off antiretroviral therapy (ART) with no sign of HIV reappearing in his body, and as time passes his position as "the person cured of HIV" becomes more secure. However, participants at the 2016 Towards a Cure Symposium, held in advance of the recent 21st International AIDS Conference (AIDS 2016) in Durban, heard about the work of a consortium of physicians and researchers who are searching for, and documenting, the fates of patients with HIV who, like Brown, have been given stem cell transplants for cancer, in an effort to abolish Brown’s distinction as the only person to be cured of HIV.

alt

Read more:

AIDS 2016: HIV Viral Load Pilot Study Shows Roll-Out Will Depend on an Educated Workforce

For viral load testing to prevent HIV treatment failure, drug resistance, and onward transmission, treatment programs will need to invest in better record-keeping and clinic procedures, human resources, demand creation, and decentralization of second-line treatment provision, a large pilot study of viral load test provision in southern Africa has found. Findings were presented last month at the 21st International AIDS Conference (AIDS 2016) in Durban.

alt

Read more:

AIDS 2016: Starting Treatment on the Day of HIV Diagnosis Improves Outcomes

Interventions to improve linkage to HIV care and retention in treatment which speed up the start of antiretroviral therapy (ART) or provide intensive support to people before starting treatment produce better retention than standard practices, researchers reported at the 21st International AIDS Conference (AIDS 2016) last week in Durban.

alt

Read more:

Coverage of 21st International AIDS Conference (AIDS 2016)

HIVandHepatitis.com coverage of the 21st International AIDS Conference (AIDS 2016), held July 18-22, in Durban, South Africa.

Conference highlights include PrEP and other biomedical HIV prevention, HIV cure research, experimental antiretroviral therapy, and access to treatment and prevention for key affected populations.

Full listing by topic

AIDS 2016 website

7/28/16

alt

AIDS 2016: Early HIV Treatment -- Mothers Say They Need Time to Think

Findings from the first randomized controlled trial to date evaluating postpartum antiretroviral therapy (ART) for women with high CD4 cell counts (over 400 cells/mm3) highlight a critical need to increase treatment acceptance in this population, according to research presented at the 21st International AIDS Conference (AIDS 2016) last week in Durban.

alt

Read more:

AIDS 2016: START Analysis Looks at Who Benefits Most from Immediate HIV Treatment

Starting antiretroviral therapy (ART) soon after HIV diagnosis led to better outcomes than delayed treatment in all population subgroups in the START trial, researchers reported at the 21st International AIDS Conference (AIDS 2016) last week in Durban. But some people saw greater risk reductions, including those over age 50, those with a lower CD4:CD8 ratio and higher viral load, and those with cardiovascular risk factors.

alt

Read more:

AIDS 2016: Once-Daily Raltegravir Works as Well as Twice-Daily For Initial HIV Treatment

A new formulation of the integrase inhibitor raltegravir (Isentress) taken once daily suppressed HIV viral load as well as the older formulation taken twice a day in people being treated for the first time, according to findings from the ONCEMRK study presented in a late-breaker session at the 21st International AIDS Conference (AIDS 2016) last week in Durban.

alt

Read more: